Apply to trial NCT05683171

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma

To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    We send your contact details and a short fit summary to the official trial contacts, with you copied.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email and copy you when we send your application to the study team.

By clicking Start, you agree to our terms of service, including sharing your contact details and fit summary with official trial contacts if you submit.